Arcus Biosciences RCUS EBITDA
EBITDA at other companies
Other financials
Where this comes from
Calculated from Arcus Biosciences’s reported figures.
The official record: Arcus Biosciences’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Arcus Biosciences's ebitda.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Arcus Biosciences's EBITDA?
- Arcus Biosciences (RCUS) reported EBITDA of -$132M in Q1 2026.
- How has Arcus Biosciences's EBITDA changed year-over-year?
- Arcus Biosciences's EBITDA decreased by 10.9% year-over-year, from -$119M to -$132M.
- What is the long-term trend for Arcus Biosciences's EBITDA?
- Over 4 years (2021 to 2025), Arcus Biosciences's EBITDA has grown at a 59.6% compound annual growth rate (CAGR), from $58M to -$376M.
- What does EBITDA mean?
- Earnings before interest, taxes, depreciation, and amortization — EBIT plus the D&A add-back from the cash-flow statement (EBITDA = EBIT + D&A). A proxy for cash earnings that strips out financing, tax, and non-cash charges.